Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer. 2021 Apr 1;127(7):1010-1020. doi: 10.1002/cncr.33433. Epub 2021 Feb 23.
Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for the management of malignant mesothelioma.
恶性间皮瘤是一种侵袭性癌症，预后不良，治疗选择有限。多年来，美国食品和药物管理局唯一批准的不可切除间皮瘤的一线治疗方法是培美曲塞加顺铂。然而，最近批准纳武单抗加伊匹单抗作为胸膜间皮瘤患者的一线治疗方法，标志着这种疾病治疗的一个重要里程碑。在这篇综述中，作者描述了治疗晚期不可切除间皮瘤患者的治疗策略的最新进展，重点介绍了免疫疗法和间皮素靶向疗法在恶性间皮瘤治疗中的应用。
